EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Carvedilol-Afforded Protection against Daunorubicin-Induced Cardiomyopathic Rats In Vivo : Effects on Cardiac Fibrosis and Hypertrophy

Wawaimuli Arozal, Flori R. Sari, Kenichi Watanabe, Somasundaram Arumugam, Punniyakoti T. Veeraveedu, Meilei Ma, Rajarajan A. Thandavarayan, Vijayakumar Sukumaran, Arun Prasath Lakshmanan, Yoshiyasu Kobayashi, Sayaka Mito, Vivian Soetikno, Kenji Suzuki

ISRN Pharmacology · 2011

DOI: 10.5402/2011/430549 ↗
AbstractBibliografische Angaben

Abstract

Anthracyclines, most powerful anticancer agents, suffer from their cardiotoxic effects, which may be due to the induction of oxidative stress. Carvedilol, a third-generation, nonselective β -adrenoreceptor antagonist, possesses both reactive oxygen species (ROS) scavenging and ROS suppressive effects. It showed protective effects against daunorubicin- (DNR-) induced cardiac toxicity by reducing oxidative stress and apoptosis. This study therefore was designed to examine the effects of carvedilol on DNR-induced cardiomyopathic rats, focused on the changes of left ventricular function, cardiac fibrosis, and hypertrophy. Carvedilol increased survival rate, prevented systolic and diastolic dysfunction, and attenuated myocardial fibrosis and hypertrophy. DNR alone treated rats showed upregulated myocardial expression of ANP, PKC- α , OPN, and TGF- β 1 and downregulation of GATA-4 in comparison with control, and treatment with carvedilol significantly reversed these changes. The results of the present study add the available evidences on the cardioprotection by carvedilol when associated with anthracyclines and explain the mechanisms underlying the benefits of their coadministration.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →